Merit Financial Group, LLC Arcutis Biotherapeutics, Inc. Transaction History
Merit Financial Group, LLC
- $9.62 Billion
- Q3 2025
A detailed history of Merit Financial Group, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Merit Financial Group, LLC holds 10,065 shares of ARQT stock, worth $241,660. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,065Holding current value
$241,660% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
248Shares Held
131MCall Options Held
407KPut Options Held
216K-
Jennison Associates LLC12.3MShares$294 Million0.14% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.5MShares$277 Million5.56% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$258 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$237 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$207 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.45B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...